Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PKLR | P30613 | 4/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115682 | 0.90 | HDAC4 (0.42) | SIGMAR1HDAC4DRD2OPRM1OPRD1 | |
| SCHEMBL23231960 | 0.87 | HDAC4 (0.50) | HDAC4OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL615903 | 0.85 | SIGMAR1 (0.57) | SIGMAR1HDAC4DRD2OPRM1OPRD1 | |
| SCHEMBL7510607 | 0.84 | DRD2 (0.46) | SIGMAR1HDAC4DRD2OPRM1OPRD1 | |
| SCHEMBL22778198 | 0.83 | HDAC4 (0.51) | HDAC4OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2276508 | 0.83 | SIGMAR1 (0.51) | SIGMAR1HDAC4DRD2OPRM1OPRD1 | |
| SCHEMBL2270695 | 0.83 | SIGMAR1 (0.47) | SIGMAR1HDAC4DRD2OPRM1OPRD1 | |
| Ethyne SCHEMBL27599449 | 0.82 | SIGMAR1 (0.54) | SIGMAR1HDAC4DRD2OPRM1OPRD1 | |
| SCHEMBL1329573 | 0.81 | HDAC4 (0.42) | SIGMAR1HDAC4OPRM1OPRD1OPRK1 | |
| SCHEMBL30824567 | 0.81 | HDAC4 (0.42) | SIGMAR1HDAC4OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312160-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3312160-A1 | HEPATITIS B ANTIVIRAL AGENTS | Novira Therapeutics Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC | 2017-11-23 | — | — | US | disclosed |
| US-9751857-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2794565-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9676747-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150259324-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. | 2015-09-17 | — | — | US | disclosed |
| US-9066932-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9061008-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150152073-A1 | Hepatitis B Antiviral Agents | NOVIRA THERAPEUTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20140178337-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. | 2014-06-26 | — | — | US | disclosed |
| US-8629274-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130251673-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013096744-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152073-A1 | Hepatitis B Antiviral Agents | HAVCR2, EIF2AK2, IRF3 | SIGMAR1 3570/4885HDAC4 893/4885DRD2 4531/4885 |
| US-20140178337-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | SIGMAR1 3570/4885HDAC4 893/4885DRD2 4531/4885 |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | SIGMAR1 3570/4885HDAC4 893/4885DRD2 4531/4885 |
| US-20130251673-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | SIGMAR1 3570/4885HDAC4 893/4885DRD2 4531/4885 |
| US-20150259324-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | SIGMAR1 3570/4885HDAC4 893/4885DRD2 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.